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Objectives: With new classes of T2DM medications offering weight reduction in 
addition to better glycaemic control, HTA agencies expect fuller accounting of the 
impact of post-trial weight trajectory assumptions on cost-effectiveness. Four alter-
native scenarios were examined using the example of the novel SGLT-2 inhibitor 
canagliflozin (CANA) in the UK treatment setting. MethOds: The importance of 
alternative assumptions was illustrated using CANA 300mg versus glimepiride (GLIM; 
1mg titrated to 6mg or 8mg) in dual therapy with metformin simulated over 40 years 
using the ECHO-T2DM model loaded with patient characteristics, treatment effects, 
and adverse event rates from the DIA3009 trial, in which CANA 300mg reduced body 
weight by –5.7% versus GLIM over 52 weeks. HbA1c was assumed to drift annually by 
0.14% for CANA (similar to metformin in ADOPT), 0.24% for GLIM (as sulphonylurea 
in ADOPT), and 0.15% for rescue therapy with insulin (initiated when HbA1c > 7.5%). 
Upon treatment discontinuation, four alternative weight-trajectory assumptions were 
applied: (A) weight change maintained permanently; (B) CANA weight reduction dis-
appears fully at treatment discontinuation, GLIM weight-gain permanent; (C) GLIM 
weight-gain permanent, forced convergence of weight upon CANA discontinuation; 
(D) weight changes disappear fully at discontinuation for both treatments. A weight 
increase was applied when insulin was initiated and proportional weight changes 
were applied when insulin dose was titrated upwards. Results: CANA 300mg gener-
ated more QALYs at modest incremental cost, resulting in ICERs of £2,766 to £4,317 in 
the scenarios. Maintaining the benefits permanently (A) generated the largest QALY 
gain (0.243); complete elimination of benefits at discontinuation (D) offered the small-
est (0.198). The proportions of incremental QALYs attributable to weight differences 
were 34.4%, 19.5%, 18.9% and 17.4% for Scenarios A to D, respectively. cOnclusiOns: 
CANA 300mg was cost-effective in each of four weight scenarios following discon-
tinuation. Further work is required to define the most clinically plausible scenarios.
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Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
inhibitor (SGLT-2) approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus (T2DM). This study evaluates the cost-effectiveness of dapagli-
flozin compared with a dipeptidyl-peptidase-IV (DPP-4) inhibitor when added to 
metformin in patients inadequately controlled on metformin alone. MethOds: 
The published and validated CARDIFF diabetes model was used to conduct the 
analysis. Clinical inputs were derived from a systematic review and network meta-
analysis. Based on clinical inputs and the United Kingdom Prospective Diabetes 
Study (UKPDS) equations, the model predicts disease progression and the number 
of micro- and macro-vascular complications, along with diabetes-specific and all-
cause mortality. The perspective of the National Health Service in England and Wales 
was adopted over a lifetime horizon. Local unit costs and utility data were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and costs. Univariate and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: Compared to a DPP-4 inhibitor, dapagliflozin was associated with 
0.076 incremental QALYs (95%CI: –0.028; 0.146) at an additional cost of £412 (95%CI: 
-£212; £853); resulting in an incremental cost-effectiveness ratio (ICER) of £5,455 
per QALY gained. The univariate analyses showed that no input parameter change 
inflated the ICER above £15,000 per QALY. The PSA estimated that dapagliflozin 
has a 81% chance to increase QALYs and costs, a 9% chance to increase QALYs 
and save costs, a 4% chance to reduce QALYs and costs and a 6% chance to reduce 
QALYs and increase costs. At a willingness-to-pay threshold of £20,000 per QALY 
gained, dapagliflozin strategy had an 86% probability to be cost-effective in this 
setting. cOnclusiOns: Dapagliflozin in combination with metformin was shown 
to be a cost-effective treatment option for T2DM patients who are inadequately 
controlled with metformin mono-therapy.
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Objectives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, includ-
ing: life extension, micro- and macrovascular events, treatment and treatment-
related adverse events (AEs), and excess bodyweight. The aim of this analysis is to 
determine which factors most impact QALY gains in an analysis of CANA 300mg 
versus SITA 100mg when combined with metformin and sulphonylurea in the UK 
treatment setting. MethOds: The ECHO-T2DM model was used to simulate CANA 
versus SITA over 40 years. ECHO-T2DM was loaded with patient characteristics, 
treatment effects, and AE rates from the DIA3015 trial. HbA1c was assumed to drift 
upwards at an annual rate of 0.14% for CANA and SITA (similar to metformin in 
the ADOPT trial). CANA and SITA were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/
mol (7.5%). Results: Hypothetical patients experienced 0.039 more QALYs when 
treated with CANA 300mg versus SITA 100mg. Because SITA had lower initial HbA1c 
lowering, it was associated with greater use of rescue medication. Patients treated 
initially with SITA, thus, had greater insulin-mediated HbA1c lowering over time so 
HbA1c values converged asymptotically (limiting differences in rates of microvas-
cular complications). There were relatively modest QALY benefits related to macro-
Carlo simulation techniques to describe the long-term incidence and progression 
of diabetes-related complications. It was used to simulate disease progression in 
a cohort of pediatric patients with baseline characteristics taken from published 
KAZAKHSTAN studies (mean age 10.4 years, duration of diabetes 4.1 years, mean 
HbA1c > 7.5%). Direct costs for 2013 were calculated from a third-party payer per-
spective. Discount rates of 5% per annum were applied to costs and 3% to clinical 
outcomes. Results: Mean undiscounted life expectancy of patients using CSII vs. 
MDI was increased by 3.58 years. The Incremental-Cost-Effectiveness-Ratio (ICER) 
for CSII was 3,935,375KZT per Quality-Adjusted-Life-Year gained based on direct 
costs only. CSII related therapy costs were partially offset by the savings due to the 
reduction in long-term complications, i.e.638,744KZT, mainly due to cardiovascu-
lar and renal diseases. Cumulative incidences of proliferative diabetic retinopathy, 
blindness, ESRD, and GRP were decreased by 25.3%, 5.6%, 28.3%, and 17.7%, respec-
tively. CSII treatment also delayed the average onset of ESRD (3.9 years), blindness 
(3.7 years), PVD (3.5 years), CHF (3.6 years), Neuropathy (3.4 years), first ulcer (4.0 
years), amputation (3.7 years), MI (3.5 years), and stroke (3.5 years). Extensive sensi-
tivity analyses showed the robustness of the results. cOnclusiOns: Using a payer’s 
perspective, our analysis showed that CSII is cost-effective over a lifetime horizon 
in children with Type 1 Diabetes in Kazakhstan (using a WTP threshold of 6,330,000 
KZT [3x GDP]) and can lead to an increase in life expectancy as well as delay and 
reduce long-term complications. When including indirect costs, CSII would be even 
more attractive from a societal perspective.
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Objectives: To assess the cost-effectiveness of using intralesional injection of 
recombinant human epidermal growth factor (rhEGF) for the treatment of severe 
non-healing diabetic foot ulcers (DFU) in highly-specialized inpatient department 
in Russian setting. MethOds: We developed a cost-effectiveness model based on 
hypothesis that use of intralesional injection of rhEGF in addition to standard treat-
ment of severe DFU (Wagner grade 3-4) would reduce the rate of amputations and 
related increased mortality in population of amputated DFU patients. For model 
inputs we used published data on the rates of amputation from retrospective study 
of intralesional injection of rhEGF and survival rates for patients with DFU with and 
without major amputations. Cost data was derived from the Russian retrospective 
study of real practice of inpatient treatment of severe DFU and reimbursement rates 
in Russian compulsory medical insurance system, cost of rhEGF treatment was pro-
vided by the manufacturer. Based on the model outputs we calculated incremental 
cost-effectiveness ratio (ICER) as the difference in costs to the difference in years 
lived during the 5-year period of observation by two cohorts of patients treated with 
only standard methods and with addition of rhEGF. Results: The use of rhEGF 
intralesional injection treatment may prevent 52 amputations and save 29.54 years 
of life in a cohort of 100 patients with severe DFU during subsequent 5-year period of 
observation. The ICER for rhEGF is estimated at EURO 27,200 per life year saved and 
does not exceed the acceptable threshold of three GDP per capita as recommended 
by WHO. The sensitivity analysis demonstrated that the results are most sensitive 
to the cost of rhEGF. cOnclusiOns: The model has demonstrated the acceptability 
of adoption of intralesional injection of rhEGF in addition to standard treatment for 
DFU in highly specialized inpatient departments.
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Objectives: To assess the cost-effectiveness of oral hypoglycaemic agents (micro-
nized glibenclamide, gliclazide, glimepiride and repaglinide) in the treatment of 
Russian patients with type 2 diabetes mellitus. MethOds: Based on the data from 
comparative studies (B. Wolffenbuttel et al., 1999; A. Holstein et al., 2001; O. Reshetko 
et al., 2007) the pharmacoeconomic profiles of glibenclamide and repaglinide, gliben-
clamide and glimepiride, glibenclamide and gliclazide were compared. It was revealed 
that glibenclamide and repaglinide, glibenclamide and gliclazide have equal efficacy 
and safety, so the cost-minimization analysis was performed. The cost-effective-
ness of glibenclamide and glimepiride was measured as total costs of medicines 
and expenses for ambulance calls for severe hypoglycemia per one patient without 
hypoglycaemic events. A one-year time horizon was adopted in the models. One-
way sensitivity analysis (SA) was carried out to assess the robustness of the results 
. Results: Compared to repaglinide and gliclazide, treatment with glibenclamide 
was associated with substantial budget savings (22,699.35 RUB and 3,566.05 RUB per 
one patient, respectively). Costs per one patient without hypoglycaemic events were 
1,137.17 RUB and 5,549.85 RUB in glibenclamide and glimepiride groups, respectively. 
Sensitivity analysis demonstrated that results are robust. cOnclusiOns: The pre-
sent study has demonstrated that administration of micronized glibenclamide is 
the most economically effective strategy in the treatment of Russian patients with 
type 2 diabetes mellitus. Treatment with micronized glibenclamide is associated 
with considerably lower costs as compared to repaglinide, glimepiride and gliclazide.
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combination with insulin versus insulin alone for patients who are inadequately 
controlled despite high doses of insulin. MethOds: The published and vali-
dated CARDIFF diabetes model was used to conduct the analysis. Clinical inputs 
were derived from a randomized clinical trial comparing dapagliflozin add-on to 
insulin with insulin regimens. Based on clinical inputs and the United Kingdom 
Prospective Diabetes Study (UKPDS) equations, the model predicts disease pro-
gression and the number of micro- and macro-vascular complications, along with 
diabetes-specific and all-cause mortality. The perspective of the National Health 
Service in England and Wales was adopted over a lifetime horizon. Local unit 
costs and utility data were assigned to the appropriate model parameters to cal-
culate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
insulin, dapagliflozin added to insulin was associated with 0.342 incremental 
QALYs (95%CI: 0.288; 0.480) at an additional cost of £1,813 (95%CI: £1,165; £2,381), 
resulting in an incremental cost-effectiveness ratio (ICER) point estimate of 
£5,295 per QALY gained. The univariate analyses showed that no input 
parameter change inflated the ICER above £15,000 per QALY. At a willingness-to-
pay threshold of £20,000 per QALY gained, the dapagliflozin treatment strategy 
was estimated to have a 100% probability of being cost-effective when compared 
to the insulin treatment strategy. These findings were shown to be robust with all 
sensitivity analyses. cOnclusiOns: Dapagliflozin was shown to be a cost-effec-
tive treatment option in combination with insulin for patients who are inad-
equately controlled with insulin alone within established UK cost-effectiveness 
thresholds.
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Objectives: To evaluate uncertainty, the NICE reference case requires estimation 
of cost-effectiveness using alternative parameter values. Because models of T2DM 
necessarily include many parameters, NICE requirements dictate a large number 
of simulations. This study assesses the relative importance of common sensitivity 
analyses by identifying key drivers of the incremental cost-effectiveness ratio (ICER) 
using the example of CANA 300mg versus GLIM (titrated from 1mg to 6mg or 8mg), 
in combination with metformin in dual therapy. MethOds: The ECHO-T2DM model 
was used to simulate CANA versus GLIM over 40 years. ECHO-T2DM was loaded 
with patient characteristics, treatment effects, and adverse event rates from the 
DIA3009 trial. HbA1c was assumed to drift annually by 0.14% for CANA (similar to 
metformin in ADOPT), 0.24% for GLIM (as sulphonylurea in ADOPT), and 0.15% for 
rescue therapy with insulin (initiated when HbA1c > 7.5%). Twenty-four one-way 
sensitivity analyses assessed the impact of drug durability, macrovascular risk equa-
tions, utility weights, and HbA1c goals. Results: In the base case, CANA 300mg 
was associated with 0.21 greater QALYs at an incremental cost of £828, generating 
an ICER of £4,050/QALY. QALY gains were driven by fewer hypoglycaemic events 
and a better weight profile. The low acquisition cost of GLIM was partially offset by 
a greater need for insulin rescue therapy earlier in treatment, more hypoglycaemic 
events, and more macrovascular complications. Assuming no difference in durabil-
ity for CANA and GLIM had the greatest impact on the ICER (£49,717), followed by 
no disutility for hypoglycaemic events (£15,733). The only other scenario having a 
noticeable impact was an HbA1c goal of 9.0% (£9,718). Alternative macrovascular 
risk engines had little impact on the ICER. cOnclusiOns: The ICER was robust 
under a large number of scenarios. Only the difference in assumed long-term GLIM 
durability reversed the interpretation of CANA as cost-effective versus GLIM using 
NICE criteria.
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Objectives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, including: 
life extension, micro- and macrovascular events, treatment and treatment-related 
adverse events (AEs), and excess bodyweight. This analysis aims to determine which 
factors most impact QALY gains using the example of CANA 300mg versus GLIM 
(titrated from 1mg to 6mg or 8mg) when combined with metformin. MethOds: The 
ECHO-T2DM model was used to simulate CANA versus GLIM over 40 years. ECHO-
T2DM was loaded with patient characteristics, treatment effects, and AE rates from 
the DIA3009 trial. HbA1c was assumed to drift upwards at an annual rate of 0.14% 
for CANA (similar to metformin in the ADOPT trial) and 0.24% for GLIM (as sulpho-
nylurea in ADOPT). CANA and GLIM were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/mol 
(7.5%). Results: Hypothetical patients experienced 0.21 more QALYs when treated 
with CANA 300mg versus GLIM. Because GLIM was associated with greater use of 
rescue medication (and extra insulin-mediated HbA1c lowering) in the simulation, 
HbA1c values converged asymptotically limiting the differences in microvascular 
complications. However, lower blood pressure for patients on CANA versus GLIM was 
associated with reductions of 2.2% to 4.1% for the rates of macrovascular outcomes 
(although associated QALY gains were small due to discounting). Differences in weight 
and especially hypoglycaemic events, related both to GLIM and to earlier initiation of 
insulin, were associated with improvements in utility (0.04 and 0.16 QALYs, respec-
vascular events, but substantial benefits attributable to weight (0.020) and especially 
hypoglycaemic events (0.024), related to CANA’s better weight-lowering and longer 
time to initiation of insulin. cOnclusiOns: Patients treated with CANA in triple 
therapy experienced an additional 0.039 QALY’s over 40 years versus patients treated 
with SITA. The primary drivers were improved weight while on agent and fewer 
hypoglycaemic events.
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Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus. This study investigates the cost-effectiveness of dapagliflo-
zin compared with a sulphonylurea (SU) when added to metformin in patients 
inadequately controlled with metformin mono-therapy. MethOds: The published 
and validated CARDIFF diabetes model was used to conduct the analysis. Clinical 
inputs were derived from a randomized clinical trial comparing dapagliflozin and 
glipizide in combination with metformin. Based on these clinical inputs and the 
United Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts 
disease progression and the number of micro- and macro-vascular complications, 
along with diabetes-specific and all-cause mortality. The perspective of the National 
Health Service in England and Wales was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
SU added to metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.467 QALYs (95%CI: 0.420; 0.665) at an additional cost of 
£1,246 (95%CI: £613; £1,637), resulting in an ICER point estimate of £2,671 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. cOnclusiOns: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
PDB57
CosT-effeCTiveness of DaPagliflozin as aDD-on To insulin for The 
TreaTmenT of TyPe 2 DiaBeTes in The neTherlanDs
van Haalen H.G.M.1, Pompen M.2, Bergenheim K.3, McEwan P.4, Townsend R.5, Roudaut M.6
1AstraZeneca, Zoetermeer, The Netherlands, 2Bristol-Myers Squibb, Woerden, The Netherlands, 
3AstraZeneca, Mölndal, Sweden, 4Swansea University, Cardiff, UK, 5AstraZeneca, Brussels, 
Belgium, 6Bristol-Myers Squibb, Rueil-Malmaison, France
Objectives: Insulin, often combined with metformin, is usually the last therapy 
option for patients with type 2 diabetes Mellitus (T2DM) who are uncontrolled on 
oral anti-diabetic drugs. Dutch guidelines recommend up-titration of insulin until 
patients maintain an HbA1c < 7%, yet in practice many patients never reach this tar-
get. Clinical evidence shows that dapagliflozin – a highly selective sodium-glucose 
cotransporter 2 (SGLT2) inhibitor – meets a need for these patients, i.e. by reduc-
ing HbA1c and weight. We studied the cost-effectiveness of dapagliflozin added to 
insulin (vs. not adding dapagliflozin) for patients with T2DM who have inadequate 
glycaemic control while on insulin. MethOds: We used the Cardiff Diabetes model 
to evaluate cost and effects of dapagliflozin added to insulin using direct compara-
tive efficacy data from a randomized placebo-controlled trial (NCT00673231). In this 
trial up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk 
factor progression and occurrence of future vascular events were estimated using 
the UKPDS 68 risk equations. Costs and utilities were derived from the literature. 
The analysis was conducted from a Dutch societal perspective using a lifetime hori-
zon. Results: The overall incidence of vascular complications was lower, and life 
expectancy was higher (19.43 LYs vs. 19.35 LYs) in those patients receiving dapagli-
flozin compared to patients not receiving dapagliflozin. Patients in the dapagliflozin 
arm obtained an incremental benefit of 0.42 QALYs. The lifetime incremental cost 
per patient in the dapagliflozin arm was € 2,293, resulting in an incremental cost-
effectiveness ratio of € 27,779 per LYG and an incremental cost-utility ratio of € 5,502 
per QALY gained. Sensitivity and scenario analyses showed that the results were 
robust to variation in modelling assumptions and input variables. cOnclusiOns: 
This analysis shows that dapagliflozin increases the quality of life of T2DM patients 
compared to current practice (up-titration of insulin), and is cost-effective in a 
Dutch health care setting.
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Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 2 
diabetes mellitus. This study assesses the costs-effectiveness of dapagliflozin in 
